Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. - Wikidata - awgldk - TriplyDB

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

http://www.wikidata.org/entity/Q34746933

about

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer Clinical heart failure in children, adolescents and young adults treated with anthracyclines and/or irradiation involving the heart region Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer Different anthracycline derivates for reducing cardiotoxicity in cancer patients Cardioprotective interventions for cancer patients receiving anthracyclines Different anthracycline derivates for reducing cardiotoxicity in cancer patients Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer Cardioprotective interventions for cancer patients receiving anthracyclines Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice Using germline genomics to individualize pediatric cancer treatments Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography.Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer.Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.Cardiovascular disease in adult survivors of childhood cancer.Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.Vascular injury in cancer survivors.Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood.Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.Increasing cardiomyopathy screening in at-risk adult survivors of pediatric malignancies: a randomized controlled trial.Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.Review of cardiotoxicity in pediatric cancer patients: during and after therapy.Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence.NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.Long-term non-cancer mortality in pediatric and young adult cancer survivors in Finland.Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation Cardiac toxicity of high-dose chemotherapy.

P2860

Q24193790-2BCB7DEC-8F64-4EBC-9CDD-4B819321525C Q24200386-C2CD746A-3520-4DE4-9777-6BA28AE23B44 Q24234511-4B47CC69-67AD-4276-B726-269DDED0DB66 Q24234833-648BE5E9-12B7-401A-BCAE-21C8EEFD3731 Q24235507-4B6A2546-A591-494B-BD92-FAEFD328610C Q24236338-B0155043-02A4-43CD-BB37-341757664944 Q24236622-24533F21-535E-479C-A89D-640D81C8A40E Q24240568-5F8FC2AF-BD25-4059-AC4D-E4DDDD04C458 Q24241097-808BEAAA-CAFC-481C-A654-8331D8259320 Q24241602-6063B0F9-EA13-43E8-AB25-440399F29F4E Q24243021-AA2A3443-EED0-490A-9A15-4815F5C074F0 Q24243810-52975C49-E9AB-4832-BF09-DCAB3A2AC125 Q24632487-1E6F06FD-ED7E-48F8-ABB1-1872BDB940D6 Q27003261-A3A691AF-EF99-426D-807E-68281B04205B Q28083073-820F70CD-9E02-428B-9045-17211087B0A2 Q30248340-16C3EEBC-49A3-47C5-A0D8-684EE8668FBA Q30491590-8D26630C-4487-490E-B32B-B51FD2F3D8EE Q33404672-4325FAC9-AF95-4516-A3B6-FEA7175A9C3F Q33549627-84D47BB1-7064-4F66-9ECD-309FE3C266D9 Q33615969-CF0C8CE1-8A80-43F2-9E4F-9193F9A3E9A9 Q33619867-409202B3-1F24-4113-86D7-D36CB14484D0 Q33671281-49C66965-CFE3-4EC5-8E2A-F3B83A3045A2 Q33815037-CD5CC1FC-15E2-4810-A481-9E239A7B61C4 Q33900003-8D3177DD-3B77-4D67-8875-215369B708C1 Q34042984-9CF0AEEE-1E5F-4700-8D39-00082E494047 Q34073681-6DC2E03F-02AB-42BF-81CF-54E16BD643E7 Q34211238-41F58EFC-7F3C-4523-A7DB-58CA744B49E6 Q34287195-2DA933BC-868E-4393-A858-815A4EEEF865 Q34563378-DB86B989-A24F-4BE4-84F1-DEB4BC833929 Q34611645-6EDA9A93-2A96-4C3B-BC43-8669315B8DBF Q34717844-05E93684-70FF-4E33-A5DD-3546183C14F0 Q35008126-376F40C9-0207-43DA-930C-EEB1CEED1252 Q35183788-00CC1565-919C-4993-9097-581B0689B934 Q35557142-08475AAC-10AD-4CE1-A682-A764F8EAFBDB Q35604952-998BE8B3-82D5-4D64-AF2B-8234A44E4047 Q35612851-D5FAA8FA-471D-4C43-BD99-CFA0214DFB04 Q35699184-37C60E51-5ADD-4204-84D2-016CD2B3C8E9 Q35797623-0DA0A0A7-0492-4C8A-A802-0487A8A58719 Q35800366-3E493A32-05EC-428D-ACD7-A6C05548FFE9 Q35949084-0743568E-0506-4C49-952E-1B3C91029067

P2860

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

http://www.wikidata.org/entity/Q34746933

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Frequency and risk factors of ...... children: a systematic review.

@ast

Frequency and risk factors of ...... children: a systematic review.

@en

Frequency and risk factors of ...... children: a systematic review.

@nl

type

label

Frequency and risk factors of ...... children: a systematic review.

@ast

Frequency and risk factors of ...... children: a systematic review.

@en

Frequency and risk factors of ...... children: a systematic review.

@nl

prefLabel

Frequency and risk factors of ...... children: a systematic review.

@ast

Frequency and risk factors of ...... children: a systematic review.

@en

Frequency and risk factors of ...... children: a systematic review.

@nl

P1433

Q34746933-EC240A09-189C-4D7D-96AD-30D931CEDA3E

P1476

Q34746933-A640E643-B50E-467A-A6EB-8B45299F022D

P2093

Q34746933-3D66979D-DCF0-4D83-AF05-5F1CA4B8A140

Q34746933-410DAA57-399F-4188-BD42-4F69CEB94DD7

Q34746933-4573B38B-767A-47BD-8E4A-02F09B264195

Q34746933-5F1F2448-978A-4F6B-B594-80737A8DDDF7

P2860

Q34746933-12D74CE9-2F83-4589-A8C0-66D62B7F1E7D

Q34746933-17FF5042-4507-40DB-A9AE-5B8568386111

Q34746933-22540AB9-E1E3-4CA3-988B-0906E7FCBE15

Q34746933-23988869-4C0F-4AE8-8C22-3E2E5CD8E65F

Q34746933-40E283D3-B86D-46DF-8EB0-10CD70C7770B

Q34746933-489F63ED-B7A7-4325-B8CA-BBBDF9947DD4

Q34746933-4AAEFAB3-B8FD-4583-B794-06D9B61091D1

Q34746933-5C3FCC3F-E373-4CE7-9382-503122D2FF6D

Q34746933-80522471-9DA1-426E-92E6-3051710C445A

Q34746933-86E2142A-AD31-431C-9242-BE0977A5BA69

P304

Q34746933-27D67BDD-4FC2-44DD-BAB5-3875EA7074AC

P31

Q34746933-E513DCFD-E660-4D17-B58B-8277F37CAAA7

P356

Q34746933-07F75B74-1B32-4DE8-8001-9BD6BDA29310

P433

Q34746933-59CEBCD0-0CD3-4285-B9D3-AEE2DE4B4609

P478

Q34746933-EFF61445-EF84-44F5-9334-DAFBC01751EB

P50

Q34746933-572EE8AF-651D-4F71-8E19-F65CA8D39A37

P577

Q34746933-EE79614F-75A4-4E4B-811E-BD6B5F15754B

P5875

Q34746933-914784F6-8F14-44F5-A8AE-4ADCAC84C119

P698

Q34746933-8DFD768E-45DD-479F-8D7A-01D48C8F367F

P356

P1433

Annals of Oncology

P1476

Frequency and risk factors of ...... children: a systematic review

@en

P2093

E C van Dalen

http://www.w3.org/2001/XMLSchema#string

H J H van der Pal

http://www.w3.org/2001/XMLSchema#string

L C M Kremer

http://www.w3.org/2001/XMLSchema#string

P A Voûte

http://www.w3.org/2001/XMLSchema#string

P2860

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling.

Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.

Early identification of anthracycline cardiomyopathy: possibilities and implications.

Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology.

Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.

Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults.

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

P304

819-829

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDF167

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Martin Offringa

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11256330

http://www.w3.org/2001/XMLSchema#string

P698

12123328

http://www.w3.org/2001/XMLSchema#string